J van Dongen - JoVE Visualize

Showing results (281-290 of 328) with videos related to

Pageof 33

Sort By:

Leukemia|February 3, 1998

Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual diseaseA Beishuizen, M A de Bruijn, M J Pongers-Willemse, et al.

Journal of Immunology (Baltimore, Md. : 1950)|November 15, 1992

A combined immunodeficiency with oligoclonal CD8+, V beta 3-expressing, cytotoxic T lymphocytes in the peripheral bloodK C Kuijpers, J J van Dongen, P van der Burg, et al.

Pediatric Research|March 10, 2000

Autoimmune lymphoproliferative syndrome (ALPS) in a child from consanguineous parents: a dominant or recessive disease?M van der Burg, R de Groot, W M Comans-Bitter, et al.

Leukemia|February 12, 1999

Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemiaM J Pongers-Willemse, T Seriu, F Stolz, et al.

Haematologica|September 8, 1999

Heteroduplex analysis of VDJ amplified segments from rearranged IgH genes for clonality assessments in B-cell non-Hodgkin's lymphoma. A comparison between different strategiesM González, D González, R López-Pérez, et al.

Calcified Tissue International|September 6, 2003

The interaction between Sillence type and BMD in osteogenesis imperfectaD J Kok, C S P M Uiterwaal, A J Van Dongen, et al.

Proceedings of the National Academy of Sciences of the United States of America|January 1, 2005

Diagnostic tool for the identification of MLL rearrangements including unknown partner genesClaus Meyer, Bjoern Schneider, Martin Reichel, et al.

Cytokines and Molecular Therapy|June 1, 1996

Detection of minimal residual disease in acute leukemia patientsJ J van Dongen, T Szczepański, M A de Bruijn, et al.

Analytical Chemistry|December 23, 2024

Immunoaffinity Intact Top-Down Mass Spectrometry for Quantification of Neuron-Specific Enolase Gamma, a Low-Abundance Protein BiomarkerSebastian A H van den Wildenberg, Sylvia A A M Genet, Maarten A C Broeren, et al.

Leukemia|November 9, 2000

Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study groupA Biondi, M G Valsecchi, T Seriu, et al.

Pageof 33

Showing results (281-290 of 328) with videos related to

Sort By:

Pageof 33

Leukemia|February 3, 1998

Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual diseaseA Beishuizen, M A de Bruijn, M J Pongers-Willemse, et al.

Journal of Immunology (Baltimore, Md. : 1950)|November 15, 1992

A combined immunodeficiency with oligoclonal CD8+, V beta 3-expressing, cytotoxic T lymphocytes in the peripheral bloodK C Kuijpers, J J van Dongen, P van der Burg, et al.

Pediatric Research|March 10, 2000

Autoimmune lymphoproliferative syndrome (ALPS) in a child from consanguineous parents: a dominant or recessive disease?M van der Burg, R de Groot, W M Comans-Bitter, et al.

Leukemia|February 12, 1999

Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemiaM J Pongers-Willemse, T Seriu, F Stolz, et al.

Haematologica|September 8, 1999

Heteroduplex analysis of VDJ amplified segments from rearranged IgH genes for clonality assessments in B-cell non-Hodgkin's lymphoma. A comparison between different strategiesM González, D González, R López-Pérez, et al.

Calcified Tissue International|September 6, 2003

The interaction between Sillence type and BMD in osteogenesis imperfectaD J Kok, C S P M Uiterwaal, A J Van Dongen, et al.

Proceedings of the National Academy of Sciences of the United States of America|January 1, 2005

Diagnostic tool for the identification of MLL rearrangements including unknown partner genesClaus Meyer, Bjoern Schneider, Martin Reichel, et al.

Cytokines and Molecular Therapy|June 1, 1996

Detection of minimal residual disease in acute leukemia patientsJ J van Dongen, T Szczepański, M A de Bruijn, et al.

Analytical Chemistry|December 23, 2024

Immunoaffinity Intact Top-Down Mass Spectrometry for Quantification of Neuron-Specific Enolase Gamma, a Low-Abundance Protein BiomarkerSebastian A H van den Wildenberg, Sylvia A A M Genet, Maarten A C Broeren, et al.

Leukemia|November 9, 2000

Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study groupA Biondi, M G Valsecchi, T Seriu, et al.

Pageof 33